About JW Therapeutics

JW Therapeutics (HKEX Stock Code: 2126) is a biotechnology company dedicated to innovation in cell immunotherapy.

Read more
Cumulative R&D investment
RMB 2 Billion+

Statistics as of June 30, 2026

Register for the longest clinical follow-up
8 Year

Statistics as of June 30, 2026

Employees
300+

Statistics as of June 30, 2026

Proprietary Intellectual Property Assets
~15

Statistics as of June 30, 2026

Clinical Studies Conducted
~15

Statistics as of June 30, 2026

Accumulated operating revenue
9.04 Billion+

Statistics as of June 30, 2026

Patients / Trial Participants
1200+

Statistics as of June 30, 2026

Qualified Treatment Centers
211

Statistics as of June 30, 2026

Carteyva® (Relmacabtagene Autoleucel Injection)

  • China's first approved Class 1 biologic CAR-T therapy 
  • Approved for three indications in China
  • Recognized with Breakthrough Therapy designation, Priority Review designation, and support from the National Major New Drug Innovation Program
  • Included in China's inaugural Innovative Commercial Health Insurance Reimbursement Drug List
Read more

LBCL

Adult patients with r/r LBCL after two or more lines of systemic therapy

FL

Adult patients with r/r follicular lymphoma (FL) in which a relapse occurs within 24 months of second-line or higher systemic treatment(Conditional Approval)

MCL

Adult patients with r/r mantle cell lymphoma (MCL) after two or more lines of systemic therapy including BTKi

Innovation Platform

Empowering innovation through advanced technology platforms and accelerating value creation through technology translation

JWeave

An End-to-End Platform for Next-Generation CAR-T Development and Clinical Translation

JWeave is JW Therapeutics' proprietary end-to-end CAR-T technology platform, spanning every critical stage of development and manufacturing—from gene of interest (GOI) discovery and vector design to process development, viral vector manufacturing, cell engineering, cell expansion, and quality control (QC) release.


Built on a foundation of standardization, modularity, and automation, the platform enables the efficient development and robust manufacturing of multi-target and armored CAR-T therapies. By integrating R&D efficiency, process excellence, and scalable manufacturing, Jweave™ accelerates the translation of next-generation cell therapies and strengthens JW Therapeutics' global innovation capabilities.

End-to-End Integration
End-to-End Integration
Modular Development
Modular Development
Multi-Target Innovation
Multi-Target Innovation

JW Vectails Lentiviral System

A Proprietary Lentiviral Vector Platform with Global Partnership Potential

JW Vectails Lentiviral System is JW Therapeutics' proprietary suspension-based lentiviral vector platform, designed to address one of the most critical aspects of cell therapy development—gene delivery and vector manufacturing. The platform integrates comprehensive capabilities across process development, scalable manufacturing, and quality control to support reliable and efficient lentiviral vector production.

The platform supports the development and manufacturing of JW Therapeutics' marketed CAR-T therapy and next-generation pipeline programs. Through technology licensing collaborations with leading global cell therapy companies, it has also demonstrated its potential in process maturity, technology transfer, and industrial scalability. Looking ahead, the platform is well positioned to support next-generation innovations, including engineered CAR-T therapies, armored CAR-T therapies, and in vivo gene delivery applications.

Process Excellence
Process Excellence
Global Collaboration
Global Collaboration
Next-Generation Innovation
Next-Generation Innovation

Manufacturing & Quality

Commercial-Scale Manufacturing for World-Class Cell Therapies

Read more
First-pass production success rate
99%
Product Delivery Rate
100%

Production performance of Beinuoda® from its market launch up to November 12, 2026

  • Commercial-Scale Production Capabilities

    6 independent production modules

    Modular layout, enabling flexible and efficient commercial production

  • End-to-End Quality System

    Strict standards and comprehensive, full-process oversight

    Adherence to applicable quality regulations, ensuring consistent product quality